The antibody response to respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a
major focus of COVID-19 research due to its clinical relevance and importance in vaccine …

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), represents an unprecedented global public health …

Background Due to anti-SARS-CoV-2 antibody decay and SARS-CoV-2 variants, vaccine
booster doses are a constant concern. It was focused on whether the third dose can quickly …

Background A vaccine against coronavirus disease 2019 (COVID-19) with highly effective
protection is urgently needed. The anti-severe acute respiratory syndrome coronavirus 2 …

Summary Two doses of Pfizer/BioNTech BNT162b2 mRNA vaccine elicit robust severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing antibodies with …

Vaccination for the prevention of severe acute respiratory syndrome coronavirus type 2
(SARS-CoV-2) infection is considered the most promising approach to control the pandemic …

This is the first study outside of clinical trials (phase I–III) evaluating the ability of the Ad5-
nCoV vaccine to generate neutralizing antibodies and the factors associated with optimal or …

Background Studies have suggested incremental short-term adverse events (AE) after
repeated vaccination. In this report, we assessed occurrence and risk factors for short-term …

The gold-standard method to evaluate a functional antiviral immune response is to titer
neutralizing antibodies (NAbs) against a viral pathogen. This is historically performed using …

The emergence of a novel coronavirus viz., severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) in late 2019 and its subsequent substantial spread produced the …